- Seegene to handle logistics support to test 50,000 girls and women ages 9-50 in Asia and Africa from August
- Seegene’s Allplex™ HPV28 Detection tests to be used to improve access to HPV screening
- Project funded by the Bill & Melinda Gates Foundation, conducted jointly by US CDC, organizations in UK & Sweden
Dr. Jerome Kim, Director General of IVI (left), and Daniel Shin, Chief Global Sales & Marketing Officer at Seegene (right) exchanged an MOU for Global HPV Burden Study Collaboration at a signing ceremony at IVI headquarters on March 31, 2023. Credit: IVI
April 3, 2023 – SEOUL, Korea – Seegene, a PCR molecular diagnostics total solution company, and the International Vaccine Institute (IVI), an international organization dedicated to vaccines, will collaborate in a research study that aims to test 50,000 people in eight countries of Asia and Africa on human papillomavirus (HPV) infection, a pathogen responsible for cervical cancer and other diseases. Seegene and IVI announced on April 3 they signed a memorandum of understanding (MOU) on the study that will utilize Seegene’s HPV diagnostic test products. The signing ceremony was held at IVI headquarters in Seoul on March 31.
The ’Global HPV Burden Study’ will be conducted in three Asian countries including Bangladesh, Nepal and Pakistan, and five African countries including Ghana, Tanzania, Zambia, Sierra Leone and the Democratic Republic of the Congo for up to five years starting from August. These are among the countries with a high burden of cervical cancer but with relatively poor access to HPV diagnostic tests. Hence this study will measure the prevalence of 28 HPV serotypes among female populations aged 9 to 50 in each country. For those 18 to 23 years old, subjects in the study will be followed up for two years to check whether a high-risk HPV infection spontaneously resolves or becomes a persistent infection and to assess its associated risk factors.
“Key findings from the Global HPV Burden Study will be used to inform HPV immunization policy and cervical cancer prevention programs going forward,” said Dr. Daniel Chul Woo Rhee, Research Scientist at IVI.
Of more than 100 HPV serotypes, the high-risk HPV group refers to serotypes with a high risk of developing cervical cancer including HPV16, HPV18, HPV31, and HPV33. Seegene’s HPV tests (Allplex™ HPV28 Detection, etc.) is designed to detect 28 high- and low-risk HPV serotypes in a single test.
Daniel Shin, Chief Global Sales & Marketing Officer at Seegene said, “It is meaningful to participate in this study through HPV products developed with Seegene’s 19 patented technologies. We hope the 28 HPV serotype tests can provide a basis for protecting the health of people in various countries.”
Dr. Jerome Kim, Director General of IVI, said, “Reliable diagnosis is crucial to successful response to infectious diseases. Seegene has significantly contributed to pandemic response in Korea and worldwide with rapid development and supply of their COVID-19 diagnostic kits. IVI is thrilled to collaborate with Seegene on a global HVP burden study utilizing their innovative tests. IVI is committed to partnering with diagnostic and vaccine companies leading innovation around the world to ensure effective diagnosis and prevention of various infectious diseases.”
IVI recently launched the Global HPV Burden Study with a $14.99 million grant from the Bill & Melinda Gates Foundation and $1 million in co-funding from the Swedish government through IVI’s European Regional Office. The US Centers for Disease Control and Prevention (CDC), London School of Hygiene & Tropical Medicine, and Karolinska Institutet in Sweden also participate in the study to utilize the results as important data for promoting international HPV vaccine programs. This harmonized, multi-country and multi-site study aims to estimate the prevalence of high-risk HPV serotype infections in girls and women to better understand the incidence of persistent HPV infection in LMICs in Asia and sub-Saharan Africa.
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, and Finland provide state funding. For more information, please visit https://www.ivi.int.